Targeting transforming growth factor-β signaling in aortopathies in marfan syndrome

Circulation Journal

Volumn 77, Issue 4, 2013, Pages 898-899

  Sawaki, Daigo ^a   Suzuki, Toru ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRILLIN 1; MITOGEN ACTIVATED PROTEIN KINASE; SMAD2 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA;

ANEURYSM; AORTA DISEASE; AORTA RUPTURE; APOPTOSIS; EDITORIAL; GENE MUTATION; HUMAN; MARFAN SYNDROME; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION;

AORTA; AORTIC ANEURYSM; FEMALE; HUMANS; MALE; MARFAN SYNDROME; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84875542380     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-13-0183     Document Type: Editorial

References (13)

1. Neptune ER, Frischmeyer PA, Arking DE, Myers L, Bunton TE, Gayraud B, et al. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet 2003; 33: 407-411.
2. Kimura N, Tanaka M, Kawahito K, Itoh S, Okamura H, Yamaguchi A, et al. Early-and long-term outcomes after surgery for acute type a aortic dissection in patients aged 45 years and younger. Circ J 2011; 75: 2135-2143.
3. Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 2006; 312: 117-121.
4. Ahimastos AA, Aggarwal A, D'Orsa KM, Formosa MF, White AJ, Savarirayan R, et al. Effect of perindopril on large artery stiffness and aortic root diameter in patients with Marfan syndrome: A randomized controlled trial. JAMA 2007; 298: 1539-1547.
5. Brooke BS, Habashi JP, Judge DP, Patel N, Loeys B, Dietz HC 3rd. Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. N Engl J Med 2008; 358: 2787-2795.
6. Lacro RV, Dietz HC, Wruck LM, Bradley TJ, Colan SD, Devereux RB, et al. Rationale and design of a randomized clinical trial of betablocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome. Am Heart J 2007; 154: 624-631.
7. Holm TM, Habashi JP, Doyle JJ, Bedja D, Chen Y, van Erp C, et al. Noncanonical TGFbeta signaling contributes to aortic aneurysm progression in Marfan syndrome mice. Science 2011; 332: 358-361.
8. Habashi JP, Doyle JJ, Holm TM, Aziz H, Schoenhoff F, Bedja D, et al. Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism. Science 2011; 332: 361-365.
9. Matt P, Schoenhoff F, Habashi J, Holm T, Van Erp C, Loch D, et al. Circulating transforming growth factor-beta in Marfan syndrome. Circulation 2009; 120: 526-532.
10. Kim KL, Yang JH, Song SH, Kim JY, Jang SY, Kim JM, et al. Positive correlation between the dysregulation of transforming growth factor-β1 and aneurysmal pathological changes in patients with Marfan syndrome. Circ J 2013; 77: 952-958.
11. Gomez D, Al Haj Zen A, Borges LF, Philippe M, Gutierrez PS, Jondeau G, et al. Syndromic and non-syndromic aneurysms of the human ascending aorta share activation of the Smad2 pathway. J Pathol 2009; 218: 131-142.
12. Akutsu K, Morisaki H, Takeshita S, Ogino H, Higashi M, Okajima T, et al. Characteristics in phenotypic manifestations of genetically proved Marfan syndrome in a Japanese population. Am J Cardiol 2009; 103: 1146-1148.
13. Radonic T, de Witte P, Groenink M, de Waard V, Lutter R, van Eijk M, et al. Inflammation aggravates disease severity in Marfan syndrome patients. PloS One 2012; 7: e32963.